Your browser is no longer supported. Please, upgrade your browser.
Settings
ALBO Albireo Pharma, Inc. daily Stock Chart
ALBO [NASD]
Albireo Pharma, Inc.
Index- P/E- EPS (ttm)-10.91 Insider Own13.53% Shs Outstand11.19M Perf Week1.02%
Market Cap386.39M Forward P/E- EPS next Y-3.03 Insider Trans-21.14% Shs Float9.38M Perf Month17.17%
Income-25.20M PEG- EPS next Q-0.80 Inst Own36.70% Short Float0.37% Perf Quarter51.78%
Sales11.40M P/S33.89 EPS this Y-104.60% Inst Trans19.50% Short Ratio0.45 Perf Half Y47.38%
Book/sh7.78 P/B4.44 EPS next Y11.10% ROA- Target Price67.40 Perf Year52.86%
Cash/sh5.10 P/C6.77 EPS next 5Y- ROE- 52W Range15.31 - 39.87 Perf YTD34.88%
Dividend- P/FCF- EPS past 5Y25.40% ROI-30.80% 52W High-13.39% Beta1.53
Dividend %- Quick Ratio7.30 Sales past 5Y- Gross Margin- 52W Low125.54% ATR2.40
Employees13 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)55.07 Volatility5.07% 8.12%
OptionableNo Debt/Eq0.02 EPS Q/Q0.60% Profit Margin- Rel Volume0.48 Prev Close35.59
ShortableYes LT Debt/Eq0.00 EarningsFeb 27 BMO Payout- Avg Volume77.18K Price34.53
Recom1.50 SMA20-2.20% SMA5015.00% SMA20038.54% Volume36,688 Change-2.98%
Nov-15-17Initiated ROTH Capital Buy $92
Jul-18-17Initiated Needham Buy $35
Jun-30-17Initiated Wedbush Outperform $58
Feb-16-17Initiated Ladenburg Thalmann Buy $40
Jan-29-18 04:01PM  Albireo Announces Closing of $74.8 Million Public Offering Including Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +5.78%
Jan-26-18 04:48PM  Largest Insider Trades of the Week GuruFocus.com +8.29%
Jan-25-18 08:45AM  Albireo Prices $65.0 Million Public Offering of Common Stock GlobeNewswire
Jan-24-18 04:01PM  Albireo Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-19-18 08:00AM  Albireo to Receive More than $55 Million(1) in Nondilutive Cash Payments GlobeNewswire +11.98%
Jan-03-18 08:00AM  Albireo Announces Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat in Japan GlobeNewswire
Dec-29-17 08:00AM  Albireo Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Dec-05-17 05:02PM  [$$] AstraZeneca Sells $10.7 Million in Albireo Stock Barrons.com
Nov-14-17 08:00AM  Albireo Reports Third Quarter 2017 Financial Results GlobeNewswire -10.73%
Nov-09-17 08:00AM  Albireo to Present at the Jefferies 2017 London Healthcare Conference GlobeNewswire
Oct-24-17 07:30AM  Featured Company News - Albireo Pharma to Present Final Results of Phase-2 Study of A4250 in Children with Cholestatic Liver Disease at The Liver Meeting(R) 2017 ACCESSWIRE
Oct-20-17 08:00AM  Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting® 2017 GlobeNewswire
Oct-16-17 08:00AM  Albireo to Host KOL Event on Progressive Familial Intrahepatic Cholestasis GlobeNewswire
Oct-03-17 08:00AM  Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting® 2017 GlobeNewswire
Sep-28-17 08:00AM  Albireo Elects Roger Jeffs to Board of Directors GlobeNewswire
Sep-26-17 08:00AM  EMAs Paediatric Committee Agrees to Albireos A4250 Pediatric Investigation Plan GlobeNewswire -6.38%
Sep-19-17 08:24AM  Albireo to Present at Investor Conferences in September GlobeNewswire
07:10AM  Featured Company News - RXi Pharma's Chief Business Officer, Alexey Eliseev, to Leave the Company ACCESSWIRE
Sep-05-17 08:00AM  Albireo to Present at 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire -11.10%
Aug-21-17 08:36AM  Albireo Reports Second Quarter 2017 Financial Results GlobeNewswire
Aug-08-17 08:00AM  Albireo to Present at Wedbush PacGrow Healthcare Conference GlobeNewswire
May-30-17 04:01PM  Albireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +14.00%
May-24-17 08:39AM  Albireo Prices $45.1 Million Public Offering of Common Stock GlobeNewswire
May-23-17 04:01PM  Albireo Announces Proposed Public Offering of Common Stock GlobeNewswire
May-18-17 08:00AM  Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC GlobeNewswire
May-16-17 08:00AM  Albireo Announces Two New U.S. Patents Allowed for A4250 with Term into 2031 GlobeNewswire
May-10-17 04:01PM  Albireo Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-27-17 08:00AM  Albireo Announces Elobixibat Data from Japan to be Presented at DDW 2017 GlobeNewswire
Apr-22-17 01:00AM  Promising Pediatric Data for Albireos A4250 to be Presented at The International Liver Congress 2017 GlobeNewswire
Apr-10-17 08:00AM  Albireo to Host KOL Meeting on Rare Pediatric Liver Diseases on April 12 GlobeNewswire
Apr-05-17 08:00AM  EASL Selects Albireos A4250 Data for Late Breaker Presentation GlobeNewswire
08:00AM  EASL Selects Albireos A4250 Data for Late Breaker Presentation
Mar-31-17 01:04PM  ALBIREO PHARMA, INC. Financials
Mar-28-17 08:00AM  Albireo to Present at Upcoming Investor Conferences GlobeNewswire
Mar-14-17 07:36AM  ALBIREO PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi -6.71%
07:30AM  Albireo Reports 2016 Financial Results GlobeNewswire
Mar-07-17 08:00AM  Albireo to Host Conference Call and Webcast on March 14 at 8:30 a.m. ET to Discuss Year-End 2016 Financial Results and Operational Highlights GlobeNewswire
Mar-01-17 08:00AM  Albireo to Present at 37th Annual Cowen and Company Health Care Conference GlobeNewswire
Feb-16-17 07:00AM  Coverage initiated on Albireo Pharma by Ladenburg Thalmann +11.39%
Feb-10-17 04:33PM  ALBIREO PHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial O
Feb-06-17 08:00AM  Albireo to Present at 19th Annual BIO CEO & Investor Conference GlobeNewswire
Feb-01-17 08:00AM  Albireo Announces Submission of New Drug Application for Elobixibat in Japan GlobeNewswire
Jan-27-17 05:01PM  ALBIREO PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Dec-30-16 01:04PM  ALBIREO PHARMA, INC. Financials
Dec-22-16 04:06PM  ALBIREO PHARMA, INC. Files SEC form 8-K/A, Financial Statements and Exhibits +8.18%
04:03PM  ALBIREO PHARMA, INC. Files SEC form 10-K, Annual Report
Dec-21-16 05:10PM  ALBIREO PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -7.33%
Dec-16-16 04:32PM  ALBIREO PHARMA, INC. Files SEC form 8-K/A, Financial Statements and Exhibits -5.45%
Nov-29-16 08:00AM  Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer GlobeNewswire
Nov-16-16 04:50PM  LifeSci Capital Initiates Coverage of Albireo Accesswire
Nov-15-16 09:01AM  Albireos Lead Product Candidate for Orphan Pediatric Liver Disease Accepted Into European Medicines Agencys PRIME Program GlobeNewswire +12.54%
Nov-04-16 05:09PM  ALBIREO PHARMA, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Creation of a Direct Fin -24.99%
Albireo Pharma Inc is biopharmaceutical company. It is engaged in developing & commercializing novel bile acid modulators to treat orphan pediatric liver diseases & gastrointestinal disorders.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Phase4 Partners Ltd10% OwnerJan 30Sale34.44100,0003,444,0471,065,447Feb 01 04:48 PM
PERCEPTIVE ADVISORS LLC10% OwnerJan 25Buy33.00275,0009,075,0001,595,000Jan 25 04:59 PM
ASTRAZENECA PLC10% OwnerDec 01Sale21.40500,00010,700,000508,141Dec 05 04:18 PM